SERAPHIN was an event-driven, multicenter, long-term (average treatment duration 2 years), randomized, double-blind, placebo-controlled phase 3 trial.2
Adapted from Pulido T, et al. N Engl J Med 2013; table 1
* The SERAPHIN study is the first and only study to demonstrate a statistically significant long-term benefit with an ERA Vs. placebo in PAH based on a composite morbidity-mortality primary endpoint.